Low-dose vs standard-dose minocycline in bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized controlled, noninferiority trial

doi:10.3748/wjg.122851

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 36

This Article

(17)

(0)

(308)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Clinical Trial

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Sep 28, 2026; 32(36): 122851
Published online Sep 28, 2026. doi: 10.3748/wjg.122851

Table 5 Cost-effectiveness ratios between the two groups

Group	E (%)	C (CNY)	C/E
Low-dose group (n = 120)	91.0%	321.7	3.54
Standard-dose group (n = 120)	92.9%	402.9	4.34

E: Effectiveness; C: Cost; C/E: Cost-effectiveness ratio.

Full Size Table

Citation: Zhu YN, Wang YB, Li L, Ren YD, Wang RR, Ji YL, Wang YP, Zhai HY, Jiang Y. Low-dose vs standard-dose minocycline in bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized controlled, noninferiority trial. World J Gastroenterol 2026; 32(36): 122851
URL: https://www.wjgnet.com/1007-9327/full/v32/i36/122851.htm
DOI: https://dx.doi.org/10.3748/wjg.122851

Zhu YN, Wang YB, Li L, Ren YD, Wang RR, Ji YL, Wang YP, Zhai HY, Jiang Y. Low-dose vs standard-dose minocycline in bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized controlled, noninferiority trial. World J Gastroenterol 2026; 32(36): 122851 [DOI: 10.3748/wjg.122851]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.